Orforglipron tablets and capsules are bioequivalent across six dose levels in adults with obesity
Trial Shows Orforglipron Tablets and Capsules Work the Same
This Phase 1 multicenter RCT evaluated orforglipron in 429 healthy adults with obesity or overweight. The study found that tablets and capsu…
A new clinical trial shows that orforglipron tablets are just as effective as capsules for people with obesity or who are overweight.
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Orforglipron Demonstrates Superior Glycaemic Control Over Dapagliflozin in Type 2 Diabetes
New oral medication shows better blood sugar control for diabetes
Phase 3 data shows orforglipron significantly outperforms dapagliflozin in HbA1c reduction for adults with inadequate glycaemic control.
A new oral treatment, orforglipron, showed significantly greater reductions in HbA1c levels compared to dapagliflozin for adults with type 2…
Incretin-based therapies outperform placebo for glycemic control and weight loss in type 2 diabetes
Newer diabetes drugs outperform for blood sugar and weight loss
This network meta-analysis of 15 incretin-based therapies (IBTs) indicates that tirzepatide, orforglipron, and semaglutide provide superior …
A large analysis finds that newer incretin-based drugs like tirzepatide and semaglutide beat placebo for blood sugar and weight loss in type…
Orforglipron shows superior HbA1c reduction versus oral semaglutide in adults with type 2 diabetes on metformin
A New Diabetes Pill Takes On Ozempic's Oral Cousin
A phase 3 RCT of 1698 adults with type 2 diabetes inadequately controlled on metformin found that once-daily oral orforglipron (12 mg or 36 …
A new once-daily diabetes pill called orforglipron lowered blood sugar better than oral semaglutide in a major head-to-head trial, but at th…
FDA Approves FOUNDAYO (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities
The FDA has approved a new daily pill called FOUNDAYO to help adults manage their weight
The FDA has approved FOUNDAYO (orforglipron), an oral GLP-1 receptor agonist, for chronic weight management in adults with obesity or overwe…
FDA approves new daily pill FOUNDAYO for adults to manage weight alongside diet and exercise.